Arterial and Plethysmographic Waveforms Variables as Predictors of Hemodynamic Response to Pneumoperitoneum

NCT ID: NCT01867814

Last Updated: 2015-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Laparoscopic surgery is frequently associated with hemodynamic changes due to pneumoperitoneum (PnP). Those complex hemodynamic changes are difficult to predict and occasionally they require active therapeutic interventions or even interruption of the surgical procedure.

One of the main hemodynamic effects of PnP is a decrease in cardiac output due to reduction of venous return and cardiac preload. Although it has been shown repeatedly that waveform variables are good predictors of cardiac output response to volume loading, the prediction hemodynamic response to decrease of preload is more complex.

The investigators hypothesize that waveform variables will predict cardiac output changes resulting from PnP. Particularly, augmented values of waveform variables before PnP will be associated with a larger decrease of cardiac output after establishing PnP.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Goals of the study

* To evaluate hemodynamic changes caused by pneumoperitoneum applied for laparoscopic surgery
* Endpoints

* Blood Pressure: Systolic, Diastolic, Mean (SBP, DBP, MBP)
* Heart Rate (HR)
* Cardiac Output/Index (CO/CI)
* Stroke Volume/Index (SV/SVI)
* Systolic Pressure Variation (SPV)
* Stroke Volume Variation (SVV)
* Plethysmographic Waveform Variation (PWV)
* Inclusion criteria

* The patients scheduled for elective laparoscopic partial hepatectomy, laparoscopic splenectomy, laparoscopic pancreatectomy - required of continuous direct blood pressure monitoring according to the type of surgery
* The patients ASA (American Society of Anesthesiologists)class III-IV scheduled for elective laparoscopic colectomy and hemicolectomy - required of continuous direct blood pressure monitoring according to their medical condition
* Pneumoperitoneum by needle application only
* Normal sinus cardiac rhythm
* Exclusion criteria

* Patients that didn't sign informed consent
* Patients ASA class I-II scheduled for elective laparoscopic colectomy or hemicolectomy
* Patients scheduled for elective laparoscopic cholecystectomy
* Patients required of monitoring by pulmonary artery catheter during the surgery according to their medical condition
* Study course, measurements and analysis

* All study participants will get an explanation and sign on informed consent at least one day prior to the day of surgery
* All study participants will receive standard anesthesia care. All patients will anesthetized intravenously with Fentanyl 2-5 mcg/kg, Propofol 1-2 mg/kg and Rocuronium 0.6-1.0 mg/kg followed by endotracheal intubation. Positive pressure ventilation with tidal volume 8 mL/kg of ideal body weight and respiratory rate 8-12 bpm to achieve end-tidal carbon dioxide of 33-37 mmHg will be applied after intubation. Anesthesia will be maintained with inhalation of Isoflurane (end-expiratory concentration at least 1.2%) in air/O2 (FiO2=0.4). Intraoperative fluid management will include an initial bolus of crystalloid solution (lactated Ringer's solution) at a dose of 7 mL/kg. Arterial blood pressure will be measured continuously through a radial arterial catheter. Pulse oximetry photoplethysmography will be monitored by index finger probe on the same side. Cardiac output will monitored noninvasively by NICOM (Non-invasive cardiac output monitor) that calculates stroke volume variation (SVV) in addition to cardiac output/cardiac index and stroke volume/stroke index
* The study procedure will begin after induction of anesthesia, preparation of the patient for surgery and insertion of the pneumoperitoneum insufflation device. The study procedure will last for 10-15 minutes and will be finished before actual intraperitoneal surgical manipulation begins
* Waveforms will be recorded from the patient monitor and values of NICOM will be noted at baseline before surgical manipulation, at PnP pressure=0 mmHg before gas insufflation but after insertion of peritoneal needle, and after PnP pressure reaches 15 mmHg (routine value for laparoscopic surgery). If after reaching PnP pressure of 15 mmHg CO will decrease by more than 20%, the PnP pressure will be reduced to 10 mmHg and recording of waveforms will be repeated after two minutes
* Standard hemodynamic parameters (heart rate, systolic and diastolic BP) and waveform variables (SPV, PWV) will be measured and calculated offline according to the records
* Parameters measured by NICOM (CO, CI, SV, SVI, SVV) will be noted at baseline (PnP pressure=0 mmHg), after PnP pressure reached 15 mmHg and after PnP pressure decreased till 10 mmHg (if necessary)

* There will be no further follow up of the patients
* We anticipate that there will be a significant number of patients with a reduction of CO by 20% or more after establishment of PnP of 15 mm Hg. We will perform comparisons between waveforms at baseline between those who decrease CO and those who do not. If there will be significant difference in variables at baseline there will be justification to perform ROC analysis to evaluate sensitivity and specificity of these variables to predict decrease in CO. In patients who will have a decrease in CO after PnP of 15 mm Hg we will compare the same variables to those that will be reached at PnP of 10 mmHg. These comparisons can help to understand the mechanisms of CO decrease during PnP
* All of the analysis of the data will be performed after removing all identifying data

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumoperitoneum Heart Output Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pneumoperitoneum

Patients undergoing laparoscopic surgery

Group Type EXPERIMENTAL

Pneumoperitoneum

Intervention Type PROCEDURE

Pneumoperitoneum 15 mmHg and 10 mmHg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumoperitoneum

Pneumoperitoneum 15 mmHg and 10 mmHg

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patients scheduled for elective laparoscopic partial hepatectomy, laparoscopic splenectomy, laparoscopic pancreatectomy - required of continuous direct blood pressure monitoring according to the type of surgery
* The patients ASA class III-IV scheduled for elective laparoscopic colectomy and hemicolectomy - required of continuous direct blood pressure monitoring according to their medical condition
* Pneumoperitoneum by needle application only
* Normal sinus cardiac rhythm

Exclusion Criteria

* Patients that didn't sign informed consent
* Patients ASA class I-II scheduled for elective laparoscopic colectomy or hemicolectomy
* Patients scheduled for elective laparoscopic cholecystectomy
* Patients required of monitoring by pulmonary artery catheter during the surgery according to their medical condition
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Carmel Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pizov Reuven, MD

Role: PRINCIPAL_INVESTIGATOR

Carmel Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Lady Davis Carmel Medical Center

Haifa, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Reuven Pizov, MD

Role: CONTACT

97248250625

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Reuven Pizov, MD

Role: primary

97248250625

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMC-12-0133-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.